A Non-interventional, Observational Post-marketing Registry of Patients Treated With Revlimid (Lenalidomide) in Taiwan

• Status: Completed
• Trial end date: 2013-07-19
• Target enrollment: 0
• Participant gender: All

Summary

The REVLIMID Registry will provide safety data from a large cohort of Taiwanese patients treated with REVLIMID. In addition, the registry will provide efficacy data and outcomes in a real-world setting (versus a clinical trial).

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Celgene; Celgene Corporation
• Treatments: Lenalidomide; Thalidomide

Criteria

Inclusion Criteria:

• Adult patients 18 years of age or older

• Patients that are being prescribed REVLIMID in combination with dexamethasone for the treatment of multiple myeloma and that have received at least one prior therapy

• Patient must be willing and able to provide informed consent

• Patients will be informed about the Registry and will have to sign a specific Registry Informed Consent Form

• Be able to ask questions prior to signing the Subject Information and Consent Form

• Be clearly informed that their involvement/participation in the registry is voluntary

• Understand that their medical care will not be altered in any way by their participation in the registry

Exclusion Criteria:

• A Patient who is unwilling or unable to provide informed consent will not be included.